Artículo
Efficacy and safety of tofacitinib in the treatment of ulcerative colitis: real-life experience in Andalusia
Autor/es | Hernández Martínez, Álvaro
Navajas Hernández, Pilar Martín Rodríguez, María del Mar Lázaro Sáez, Marta Olmedo Martín, Raúl Nuñez Ortiz, Andrea Argüelles Arias, Federico Vázquez Morón, Juan María |
Departamento | Universidad de Sevilla. Departamento de Medicina |
Fecha de publicación | 2022 |
Fecha de depósito | 2024-04-29 |
Publicado en |
|
Resumen | Background: tofacitinib is a Janus kinase inhibitor approved
for the treatment of moderate-severe ulcerative colitis (UC).
This study aimed to evaluate its efficacy in a real-life setting.
Methods: a retrospective and ... Background: tofacitinib is a Janus kinase inhibitor approved for the treatment of moderate-severe ulcerative colitis (UC). This study aimed to evaluate its efficacy in a real-life setting. Methods: a retrospective and multicenter observational study was performed with UC patients treated with tofac itinib. Short and long-term treatment effectiveness, treat ment survival, need for dose escalation and safety were analyzed. Clinical response and remission were defined in accordance with the partial Mayo score. Results: seventy-four patients were included, 98.3 % had received prior biological treatment, 55.4 % with three or more biologicals and up to 64.9% with two or three differ ent mechanisms of action. Clinical remission and response rates were 37.8 % and 77 % at eight weeks, and 41.8 % and 70.1 % at 16 weeks. With regard to non-responders at eight weeks, 37.5 % achieved a delayed clinical response at 16 weeks. Mean treatment duration was 19 months (95 % CI: 16-22), with a treatment survival of 56 % at 28 months, and remission and response rates at 24 months of 53.8 % and 61.5 %. Twenty-three treatments were withdrawn, most of them (18) during the induction period. There were adverse events in a quarter of the patients; only four were severe and led to treatment discontinuation. Conclusion: tofacitinib has a demonstrated efficacy in clin ical practice to induce and maintain clinical response in treatment-refractory UC patients, with an acceptable safety profile. |
Cita | Hernández Martínez, Á., Navajas Hernández, P., Martín Rodríguez, M.d.M., Lázaro Sáez, M., Olmedo Martín, R., Nuñez Ortiz, A.,...,Vázquez Morón, J.M. (2022). Efficacy and safety of tofacitinib in the treatment of ulcerative colitis: real-life experience in Andalusia. Revista Española de Enfermedades Digestivas, 114 (9), 516-521. https://doi.org/10.17235/reed.2022.8380/2021. |
Ficheros | Tamaño | Formato | Ver | Descripción |
---|---|---|---|---|
Efficacy and safety.pdf | 959.2Kb | [PDF] | Ver/ | |